The therapeutic armamentarium of acute myeloid leukemia (AML) has rapidly expanded in
the past few years, driven largely by translational research into its genomic landscape and …

FLT3 mutations are the most common genetic aberrations found in acute myeloid leukemia
(AML) and associated with poor prognosis. Since the discovery of FLT3 mutations and their …

The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in approximately one third of patients
with acute myeloid leukemia (AML), either by internal tandem duplications (FLT3-ITD), or by …

The receptor tyrosine kinase fms-like tyrosine kinase 3 (FLT3), involved in regulating
survival, proliferation, and differentiation of hematopoietic stem/progenitor cells, is …

Although transcription factor CCAAT-enhancer binding protein α (C/EBPα) is critical for
normal and leukemic differentiation, its role in cell and metabolic homeostasis is largely …

Acute myeloid leukemia (AML) is a highly heterogeneous hematopoietic malignancy
characterized by excessive proliferation and accumulation of immature myeloid blasts in the …

Haematopoiesis is governed by haematopoietic stem cells (HSCs) that produce all lineages
of blood and immune cells. The maintenance of blood homeostasis requires a dynamic …

The receptor tyrosine kinase FLT-3 is frequently mutated in acute myeloid leukemia;
however, current small molecule inhibitors suffer from limited efficacy in the clinic …

Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are often present in newly
diagnosed acute myeloid leukemia (AML) patients with an incidence rate of approximately …

Mutations in the fms-like tyrosine kinase 3 (FLT3) gene are detected in approximately one-
third of patients with newly diagnosed acute myeloid leukemia (AML). These consist of the …